- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07822607
Intravenous Iron in the Management of Drug-resistant Restless Legs syndromeI (IRON-RLS)
2026년 9월 11일 업데이트: University Hospital, Montpellier
Intravenous Iron in the Management of Drug-resistant Restless Legs Syndrome: a Randomized Controlled Delayed-start Trial. IRON-RLS
The pathophysiology of restless legs syndrome (RLS) is not well understood: it is thought to involve intracerebral iron deficiency and dopaminergic dysregulation.
This study aims to evaluate the use of intravenous ferric carboxymaltose in patients with restless legs syndrome (RLS).
This study plans to include individuals with RLS, who will be divided into two groups:
- One group will receive intravenous iron immediately after the baseline polysomnography
- The second group will receive intravenous iron 3 months after randomization. In total, participants will be followed for 6 months, during which time they will be required to complete questionnaires regularly, undergo blood draws, and have two polysomnography tests.
연구 개요
상태
아직 모집하지 않음
정황
연구 유형
중재적
등록 (추정된)
66
단계
- 2 단계
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 연락처
- 이름: Yves DAUVILLIERS, MD - PhD
- 전화번호: 0033 467 3374 78
- 이메일: y-dauvilliers@chu-montpellier.fr
연구 장소
-
-
-
Montpellier, 프랑스
- CHU de Montpellier
-
연락하다:
- Yves DAUVILLIERS, MD PhD
- 전화번호: 033 4 6733 7478
- 이메일: y-dauvilliers@chu-montpellier.fr
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
아니
설명
Inclusion Criteria:
- Age ≥ 18 years;
- Weight ≥ 50 kg;
- Drug-resistant RLS;
- Severe to very severe RLS (IRLSSG-Q score > 20), persistent or recurrent for more than one month;
- Treatment with dopamine agonists without exceeding the recommended doses (ropinirole ≤ 2 mg/day, pramipexole ≤ 0.54 mg/day, rotigotine ≤ 3 mg/day);
- Treatment with dopamine agonists and/or α2δ ligands and/or opioids that has been stable for at least 3 months;
- In cases of sleep apnea syndrome, treatment with continuous positive airway pressure (CPAP);
- Participants were required to be fluent in spoken and written French, be enrolled in a health insurance plan, agree to the automated processing of anonymized confidential data, and have provided written, informed consent for the study.
Exclusion Criteria:
- Iron supplementation (oral or intravenous) within 3 months prior to enrollment and throughout the study period
- Serum ferritin < 50 µg/L or > 300 µg/L;
- Transferrin saturation < 20% or > 45%;
- Hemochromatosis;
- RLS augmentation syndrome ;
- Treatment with neuroleptics or antidepressants;
- Allergy to iron;
- Severe infectious or inflammatory disease within the past 3 months;
- RLS associated with chronic kidney disease, pregnancy, or a clinically significant neurological or psychiatric disorder;
- Severe sleep apnea syndrome (AHI > 30/h) that is untreated, or in cases where treatment is refused or has failed;
- Known allergy, inflammatory, or immune disorder;
- History of severe asthma, eczema, or any other atopic allergy;
- Pregnancy or breastfeeding;
- Also excluded are patients participating in another research study, those deprived of their liberty by judicial or administrative order, those living in a medical facility, those subject to a legal protection order, or those from whom consent could not be obtained.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Immediate treatment
The treatment will be administered at at baseline (V1), immediately after the baseline polysomnography
|
administration of 1 g of CMF for 2 hours under medical monitoring
Administration of 1 g of CMF for 2 hours under medical monitoring
Randomization in the arm "Immediate treatment" or "Delayed-onset treatment"
Completion of questionnaires and scales: European Quality of Life 5 Dimensions (EQ-5D), Epworth Sleepiness Scale (ESS), Clinical Global Impression (CGI), Patient Global Impression (PGI), Beck Depression Inventory-II (BDI-II), Augmentation Severity Rating Scale (ASRS), International Restless Legs Study Group Severity Rating Scale (IRLSSG-Q), International Restless Legs Syndrome (IRLS), Insomnia Severity Index (ISI)
Lumbar puncture performed according to standard practice
During inclusion visit (Day 0) only for women of childbearing age
|
|
활성 비교기: Delayed-onset treatment
The treatment will be administered at 12 weeks
|
administration of 1 g of CMF for 2 hours under medical monitoring
Administration of 1 g of CMF for 2 hours under medical monitoring
Randomization in the arm "Immediate treatment" or "Delayed-onset treatment"
Completion of questionnaires and scales: European Quality of Life 5 Dimensions (EQ-5D), Epworth Sleepiness Scale (ESS), Clinical Global Impression (CGI), Patient Global Impression (PGI), Beck Depression Inventory-II (BDI-II), Augmentation Severity Rating Scale (ASRS), International Restless Legs Study Group Severity Rating Scale (IRLSSG-Q), International Restless Legs Syndrome (IRLS), Insomnia Severity Index (ISI)
Lumbar puncture performed according to standard practice
During inclusion visit (Day 0) only for women of childbearing age
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
IRLSSG-Q score
기간: From Day 0 to Week 12
|
IRLSSG-Q : International Restless Legs Study Group Severity Rating Scale allows for the quantification of the severity of restless legs syndrome
|
From Day 0 to Week 12
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Periodic Limb Movements during Sleep (PLMS) index
기간: From V1 (Day 0) to V5 (week 24)
|
The PLMS Index measures the average number of involuntary leg movements per hour of sleeping during polysomnography.
15 or more per hour: Considered abnormal for adults and may suggest a condition called Periodic Limb Movement Disorder (PLMD) if it disrupts your sleep.
|
From V1 (Day 0) to V5 (week 24)
|
|
Total sleep time
기간: From day 0 to week 24
|
Total sleep time measured in minutes during polysomnography.
|
From day 0 to week 24
|
|
Sleep latency
기간: From Day 0 to week 24
|
Length of time in minutes it takes to transition from full wakefulness to the lightest stage of sleep after the lights are turned off.
|
From Day 0 to week 24
|
|
Sleep time at stage 1-2 during polysomnography
기간: From Day 0 to week 24
|
Time spent in stage 1-2 sleep measured in hours and minutes during polysomnography
|
From Day 0 to week 24
|
|
Sleep time at stage 3 during polysomnography
기간: From Day 0 to week 24
|
Time spent in stage 3 sleep measured in hours and minutes during polysomnography
|
From Day 0 to week 24
|
|
Micro-awakenings index (MAI)
기간: From Day 0 to week 24
|
The Micro-awakenings index measures the number of brief awakenings that the person does not notice per hour of sleep.
|
From Day 0 to week 24
|
|
Apnea-hypopnea index (AHI)
기간: From Day 0 to week 24
|
The apnea-hypopnea index (AHI) measures the average number of interruptions or reductions in breathing per hour of sleep to assess the severity of sleep apnea.
|
From Day 0 to week 24
|
|
Average arterial oxygen saturation (SaO2)
기간: From Day 0 to Week 24
|
The unit of measurement for SaO2 is the percentage (%).
|
From Day 0 to Week 24
|
|
Oxygen desaturation index (IDO)
기간: From Day 0 to week 24
|
The oxygen desaturation index (IDO) measures the number of significant drops in blood oxygen levels per hour of sleep.
|
From Day 0 to week 24
|
|
Serum ferritin
기간: From Day 0 to week 24
|
From Day 0 to week 24
|
|
|
Transferrin saturation coefficient
기간: From Day 0 to Week 24
|
From Day 0 to Week 24
|
|
|
Epworth Sleepiness Scale (ESS)
기간: From Day 0 to Week 24
|
A measure of excessive daytime sleepiness that quantifies the impact of the condition on alertness throughout the day.
Eight everyday situations are rated (for example, watching television, riding as a passenger in a car, sitting quietly in a public place).
Each situation is scored from 0 to 3 based on the likelihood of falling asleep.
Total score 0-24; a score of ≥10 suggests excessive sleepiness
|
From Day 0 to Week 24
|
|
European Quality of Life 5 Dimensions (EQ-5D)
기간: From Day 0 to Week 24
|
EQ-5D: this self-administered questionnaire assesses five dimensions (mobility, daily activities, self-care, pain/discomfort, anxiety/depression) as well as overall health status on a visual scale from 0 to 100
|
From Day 0 to Week 24
|
|
Clinical Global Impression (CGI)
기간: From Day 0 to Week 24
|
The clinician's overall assessment of the illness, including CGI-S (severity) and CGI-I (change).
7-point scale: CGI-S 1 = normal, 7 = extremely ill; CGI-I 1 = markedly improved, 7 = markedly worsened
|
From Day 0 to Week 24
|
|
Patient Global Impression (PGI)
기간: From Day 0 to Week 24
|
Patient's overall perception of the severity of their illness or change; a simple 7-point scale, self-reported.
A high score is associated with patients perceiving their symptoms as severe
|
From Day 0 to Week 24
|
|
Beck Depression Inventory-II (BDI-II)
기간: From Day 0 to Week 24
|
BDI-II: a self-administered questionnaire consisting of 21 items that assess the severity of depressive symptoms over the past two weeks; score range: 0-63; thresholds: 0-13 (mild), 14-19 (moderate), 20-28 (severe), ≥29 (severe)
|
From Day 0 to Week 24
|
|
Augmentation Severity Rating Scale (ASRS)
기간: From Day 0 to Week 24
|
A 7-item self-administered questionnaire used to quantify the severity of the augmentation syndrome in patients treated with dopamine agonists.
It assesses the worsening or early onset of RLS symptoms and their impact on sleep and daily activities
|
From Day 0 to Week 24
|
|
Insomnia Severity Index (ISI)
기간: From Day 0 to week 24
|
To assess the severity of the patient's insomnia, taking into account both the quantity and quality of sleep, as well as its impact on daily functioning (fatigue, concentration, mood).
A 7-item self-report questionnaire scored from 0 to 4, with a total score of 0-28; 0-7 indicates no insomnia, 8-14 mild, 15-21 moderate, and 22-28 severe insomnia
|
From Day 0 to week 24
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (추정된)
2026년 10월 1일
기본 완료 (추정된)
2029년 4월 1일
연구 완료 (추정된)
2030년 10월 1일
연구 등록 날짜
최초 제출
2026년 8월 28일
QC 기준을 충족하는 최초 제출
2026년 9월 11일
처음 게시됨 (실제)
2026년 9월 16일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2026년 9월 16일
QC 기준을 충족하는 마지막 업데이트 제출
2026년 9월 11일
마지막으로 확인됨
2026년 9월 1일
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- RECHMPL25_0557
- 2026-525613-31-00 (씨티스)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
아니요
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
아니
미국 FDA 규제 기기 제품 연구
아니
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .